Skip to search formSkip to main contentSkip to account menu

danoprevir

National Institutes of Health

Related topics

Related topics

5 relations

Narrower (3)

ITMN-191R 7227RG 7227

Broader (2)

LactamsSulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis
Background and aimEffective and safe antiviral treatment regimens are needed for patients with chronic hepatitis C (CHC) and… 
2015
2015
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
ABSTRACT While earlier therapeutic strategies for the treatment of hepatitis C virus (HCV) infection relied exclusively on… 
2015
2015
Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir
Background and ObjectivesUnderstanding transmembrane transport provides a more complete understanding of the pharmacokinetics of… 
2014
2014
Current race in the development of DAAs (direct-acting antivirals) against HCV.
2014
2014
Identification of the NS5B S282T Resistant Variant and Two Novel Amino Acid Substitutions That Affect Replication Capacity in Hepatitis C Virus-Infected Patients Treated with Mericitabine and…
ABSTRACT Baseline and posttreatment samples from hepatitis C virus (HCV) genotype (GT) 1-infected patients who received a… 
2013
2013
Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders
ABSTRACT Danoprevir (DNV) is a hepatitis C virus (HCV) protease inhibitor that achieves high sustained virologic response (SVR… 
2013
2013
Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin
BackgroundDanoprevir (RG7227) is a potent macrocyclic inhibitor of the hepatitis C virus NS3/4A protease, which is currently in… 
2012
2012
Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics
Background and ObjectiveDanoprevir, a potent, selective inhibitor of the hepatitis C virus (HCV) NS3/4A protease, is metabolized… 
Highly Cited
2011
Highly Cited
2011
New Merck and Vertex drugs raise standard of care in hepatitis C
2010
2010
Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
Danoprevir (ITMN-191; RG-7227), under development by InterMune Inc and Roche Holding AG, is a promising, potent NS3/4A protease… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)